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FAMILIAL  NONMEDULLARY  THYROID  CANCER  (Abstract):  Follicular  cell-derived 
thyroid cancer which represents 90-95% of all thyroid malignancies may occur in at least 5% of 
cases  as  familial  disease.  Familial  nonmedullary  thyroid  cancer  (FNMTC)  is  defined  as  the 
existence of two or more first degree relatives affected within a family. FNMTC may occur in two 
situations: pure FNMTC in which FNMTC is the predominant neoplasm although other cancers 
may occur with increased frequency (non syndromic NMTC) and syndromic NMTC in which 
other cancers or association of tumors are the most predominant feature and thyroid cancer is 
associated with known frequency. Most patients with syndromic NMTCs are asymptomatic, but 
genetic screening for the syndrome allows an early diagnosis and adequate surgery. Syndromic 
and  non-syndromic  FNMTC  may  represent  5-15%  from  all  follicular  cell-derived  thyroid 
carcinomas.  Four  susceptibility  loci  for  pure  FNMTC  have  been  described:  TCO  –  familial 
thyroid  carcinoma  with  oxyphilia  on  chromosome  19p13.2,  FPTC/PRN  –  familial  papillary 
thyroid  carcinoma  with  papillary  renal  neoplasia  (carcinoma)  on  chromosome  1q13.2-1q22, 
NMTC1 – non medullary thyroid carcinoma type 1 on chromosome 2q21, NMG1 – multinodular 
goiter  with  papillary  thyroid  carcinoma  on  chromosome  14q32.  Inheritance  is  autosomal 
dominant, but the candidate genes are unknown. Most authors agree that pure FNMTC have a 
more  aggressive  behavior:  multifocality,  bilaterality,  association  with  other  thyroid  disease 
(nodules and thyroiditis), trend to spread locally and in lymph nodes, higher recurrence rate, lower 
disease-free survival. Syndromic FNMTCs occur in the following syndromes in which FNMTC 
occurs  with  a  known  frequency:  Familial  Adenomatous  Polyposis  and  Gardner’s  syndrome 
(associated  FNMTC  -  5%),  PTEN-hamartoma  tumor  syndrome  (PTEN/PHTS  -  associated 
FNMTC  -  10%),  Carney’s  complex  (associated  FNMTC  -  10-25%),  Werner’s  syndrome 
(associated FNMTC - up to 18%). Knowing the aggressiveness of FNMTCs, affected individuals 
must be prospectively researched by screening, aggressively treated and closely monitored. Their 
relatives  must  be  also  monitored  for  early  diagnosis  known  the  phenomenon  of  genetic 
anticipation. 
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INTRODUCTION 
Follicular  cell-derived  thyroid  cancer 
represents  90-95%  of  all  thyroid 
malignancies  and  at  least  5%  are  familial 
diseases  [1-3].  Among  thyroid  cancer 
papillary form the most frequent type. After 
introduction  of  thyroid  ultrasound  in  the 
routine examination thyroid cancer became 
the  cancer  with  the  highest  increase  in 
prevalence in the last years [1].  
Although  most  of  thyroid  cancers 
occur  as  sporadic  forms,  familial 
nonmedullary  thyroid  cancers  (FNMTC) 
have been described by Stoffer (1986), Loh 
(1997)  quoted  by  Capezonne  (2008),  and 
seem  to  be  more  common  than  previously 
thought [4].  
The  first  definition  of  follicular  cell-
derived  thyroid  carcinoma  was  that  of 
occurrence of in more than one member of a 222      Mogoş V. et al. 
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family  but  was  criticized  because  the 
presence of only 2 affected individual could 
be a simply fortituos association.  
Now  FNMTC  is  defined  as  the 
existence  of  two  or  more  first  degree 
relatives affected within a family [cited by 4] 
or as follicular cell-derived cancers in three 
or  more  first  degree  relatives  in  a  family 
[5,6].  After  Capezzone  (2009)  only  seven 
families  with  three  or  more  affected 
members may be considered for clinical and 
genetic  screening  for  non-syndromic 
FNMTC  [7].  FNMTC  may  occur  in  two 
situations: pure FNMTC in which FNMTC 
is the predominant neoplasm although other 
cancers may occur with increased frequency 
(non  syndromic  NMTC)  and  syndromic 
NMTC in which other cancers or association 
of tumors are the most predominant feature 
and thyroid cancer is associated with known 
frequency  [2,5,7,8].  Most  patients  with 
syndromic  NMTCs  are  asymptomatic,  but 
genetic  screening  for  the  syndrome  allows 
an early diagnosis and adequate surgery [5].  
Classification of FNMTC (after Nose 
and Capezzone) [3,5.7]: 
A) Non-syndromic:  familial  tumor 
syndromes with preponderance of NMTC 
1) Familial  papillary  thyroid  carcinoma 
with or without oxyphilia- FPTC 
2) FPTC associated  with renal papillary 
neoplasia 
3) Familial NMTC type 1 
4) FPTC with multinodular goiter 
B) Syndromic:  familial  tumor  syndromes 
with  preponderance  of  non-thyroidal 
tumors and in which NMTC occurs with a 
known frequency: 
1) Familial adenomatous polyposis (FAP) 
and  Gardner’s  syndrome  (a  FAP 
variant) 
2) PTEN-hamartoma  tumor  syndrome 
(Cowden’s syndrome) 
3) Carney’s complex 
4) Werner’s syndrome 
5) Pendred syndrome 
 
FREQUENCY OF NMTC 
The risk of developing NMTC among 
first  degree  relatives  of  an  affected 
individual  is  3-9  folds  higher  than  in 
individuals with no affected relative and the 
frequency  of  familial  papillary  thyroid 
cancer is the highest of all cancer types [4]. 
The frequency of FNMTC is reported in the 
literature as follows: 
Syndromic  and  non-syndromic 
FNMTC  may  represent  5-15%  of  all 
follicular  cell-derived  thyroid  carcinomas. 
Non-syndromic  FNMTC  represents  10.5% 
of  these  carcinomas  [5].  Five  percents  of 
thyroid cancers have an evidence of familial 
association  [1,2,9,10]  and  5%  of  NMTC 
could be diagnosed on the basis of familial 
predisposition  [11].  FNMTCs  represent 
8.8%  of  all  thyroid  cancers  and  9.4%  
of  patients  with  only  papillary  thyroid 
cancers [12].  
 
GENETICS OF FNMTC 
Pure (non-syndromic) FNMTC 
Population-based  studies  suggest  that 
pure FNMTC is a true hereditary syndrome 
[13]  which  has  an  autosomal  dominant 
inheritance with reduced penetrance or age-
related  partial  penetrance  [14].  Four 
susceptibility loci for non-syndromic NMTC 
have been described in different families but 
real  genetic  defects  are  still  not 
demonstrated [1,3-5,10,15,16]: 
TCO – familial thyroid carcinoma with 
oxyphilia  on  chromosome  19p13.2. 
Inheritance  is  autosomal  dominant  but 
candidate gene is not known. 
FPTC/PRN – familial papillary thyroid 
carcinoma  with  papillary  renal  neoplasia 
(carcinoma)  on  chromosome  1q13.2-1q22. 
Type of inheritance is autosomal dominant, 
candidate gene is unknown. Papillary renal 
neoplasia has a close histology with that of 
papillary  thyroid  carcinoma  [9].  Other 
neoplasm  may  be  associated  with 
FPTC/PRN [5].  
NMTC1  –  non  medullary  thyroid 
carcinoma  type  1  on  chromosome  2q21. 
Inheritance and candidate gene is not known. 
NMG1  –  multinodular  goiter  with 
papillary thyroid carcinoma on chromosome 
14q32.  Inheritance  is  autosomal  dominant, 
but the candidate gene is unknown. Familial nonmedullary thyroid cancer    223 
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Microsatelite linkage analysis allowed 
the  description  of  other  candidate  locuses 
and  genes  for  FNMTC  such  as:  FTEN  on 
chromosome 8p23.1, genes on chromosomes 
1q.21 and 6q.22 [10]. FPTC was associated 
with  germ-line  imbalanced  telomere-
telomerase  complex  with  increased  copy 
number and expression of telomerase when 
compared with sporadic PTC [4].  
The analysis of different familial cases 
of FNMTCs by linkage desechilibrium and 
loss  of  heterozigosity  showed  that  above-
mentioned mutations are not as frequent as 
previously  thought,  but  BRAF  V600  and 
RAS  mutations  already  known  to  be 
involved  in  sporadic  PTC  tumorigenesis 
have been found1.  
In  a  study  on  14  individuals  with 
FNMTC 35% had loss of heterozigosity for 
three suscepyibility loci: NMTC1, TCO and 
MNG1  and  41.4%  had  BRAF  V600 
mutations [11]. In other study, Xing on 40 
cases  of  FNMTC, no  BRAF mutation was 
found [cited by 16]. In syndromic FNMTCs 
there have been not found mutations for the 
following genes [1,15]: RET, MET, MEK1, 
MEK2,  TRKA/NTR1C,  TSH-R,  PTEN  or 
APC. 
 
TUMOR  CHARACTERISTICS  IN 
FNMTC 
FNMTCs show a general characteristic 
of  “genetic  anticipation”  defined  by  Mc 
Innis 1996 [cited by 4] as “occurrence of a 
genetic disorder at progressively earlier age 
and  increased  aggressiveness  in  successive 
generations”.  Cohort-based  studies  on 
FNMTCs  have  shown  some  characteristics 
which involve a specific approach of these 
tumors [4,5,13,17]: 
-  tumors are more frequently multifocal 
and bilateral; 
-  in  the  offsprings  they  appear  at 
younger  ages  and  have  a  more 
aggressive  behavior  (especially  if  a 
proband  was  already  seen  in  the 
family)  [4,18];  the  aggressiveness  of 
FNMTCs  compared  with  sporadic 
disease  is  controversial,  but  may  be 
more  important  if  the  index  case  in 
families  with  3  or  more  affected 
individuals [13] or in another study the 
aggressiveness  of  FNMTC  is 
independent  of  affected  members  in 
the family [19].  
-  FNMTCs  have  more  frequent 
ipsilateral  and  controlateral  lymph 
node  involvement  and  local  invasion 
that explain a higher reccurence rate, a 
worse outcome and a shorter disease-
free survival [4,5,10,17,19].   
-  association  with  other  thyroid 
disorders.  Thyroid  autoimmunity  is 
higher in families with more than one 
affected member [20]. Compared with 
sporadic disease FNMTC occurs more 
frequently in association with multiple 
benign  adenomatous  nodules, 
multinodular  hyperplasia  and 
lymphocytic  thyroiditis  [17,21].  An 
analysis  of  50  individuals  with 
FNMTCs  in  8  families  showed  that 
26%  of  them  have  more  than  one 
thyroid lesion [8]. 
A  study  including  1502  individuals 
with  follicular  cell-derived  thyroid  cancers 
Mazeh demonstrated in those with FNMTC 
compared with sporadic forms the following 
characteristics [19]: multicentricity - 48% vs 
22%,  local  invasion  -  54%  vs  0.6%,  more 
frequent  local  invasion  and  higher 
reccurence  rate  -  24%  vs  12%.  Zhao  J.  in 
study  of  36  FPTCs  from  15  families  has 
found:  bilaterality  in  33.3%  of  cases, 
multifocality  in  55.6%,  lymph  node 
metastases in 75%, coexistence with benign 
thyroid lesions in 27% of cases [21]. 
The  main  features  of  FNMTCs  were 
summarized  by  Nose  and  Mc  Donald  as 
follows [5,6]: 
-  early age of diagnosis; 
-  association  with  benign  thyroid 
diseases; 
-  higher  male  to  female  ration  than 
usually seen in thyroid cancer; 
-  multifocality and bilaterality; 
-  more aggressive behavior; 
-  higher  trend  to  spread  out  of  the 
thyroid; 
-  higher rate of distant metastases; 224      Mogoş V. et al. 
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-  higher  rate  of  persistence  and 
recurrence; 
-  lower survival rate; 
-  only  candidate  locuses  without 
candidate genes. 
Taking  into  account  these  features, 
FNMTCs  must  be  aggressively  treated  by 
total  thyroidectomy,  central  compartment 
neck dissection, lateral functional (modified) 
neck  dissection  [15],  radioiodine 
postoperative  ablation,  TSH  suppressive 
treatment  and  close  thyroglobulin 
monitoring  [8,18].  Clinical  and  neck 
ultrasound  monitoring  of  the  relatives  are 
mandatory [18].  
 
SYNDROMIC NMTC 
 
1.  Familial  adenomatous  polyposis 
(FAP)  and  Gardner’s  syndrome  (a  FAP 
variant)  are  atusomal  dominant  syndromes 
due to APC (Adenomatous Polyposis Coli) 
tumor  suppressor  gene  locatied  on  the 
chromosome  5q21.  Birth  incidence  of  the 
disease  varies  from  1/8300  to  1/11300-
1/37000  [22].  Classic  FAP  becomes 
manifested from the second decade of life by 
the appearance of thousands of adenomatous 
polyps in the colon and rectum. Attenuated 
FAP  (AFAP)  shows  fewer  adenomatous 
polyps,  later  age  of  appearance  and  lower 
cancer  risk  [22].  Gardner’s  syndrome  is  a 
variant of FAP that includes other diseases. 
5% of patients with FAP develop follicular 
cell-derived  thyroid  carcinomas.  1-2% 
develops PTC [23]. Extrathyroidal diseases 
may be: osteomas of the mandible, fibrous 
dysplasia  of  the  skull,  fibrous  dermoid 
tumors,  hypertrophic  retinal  pigmented 
epiyhelium [5]. FAP associated PTC shows 
a  particular  histology:  the  cribriform-
morular varian or may be a classic PTC with 
sclerosis [24]. 
2. PTEN-hamartoma tumor syndrome 
(PTEN/PHTS)  is  an  autosomal  dominant 
inherited syndrome due to gene deletion of 
PTEN  (Phosphatase  and  Tensin  homolog) 
tumor  suppressor  gene  located  on 
chromosome 10p23.2. It includes Cowden’s 
syndrome  (CS),  Bannayan  –  Riley  - 
Ruvalcalba syndrome, Proteus syndrome and 
Proteus-like syndrome [5,25].  
PTEN  is  a  phosphatase  for 
phosphoinositol 3,4,5 triphosphate involved 
in cell cycle, genomic stability and apoptosis 
[26]. Non thyroidal  diseases  in the PTEN-
hamartoma  tumor  syndrome  are  [5,25,27]: 
hamartoma  of  the  breast,  colon, 
endometrium,  uterus,  brain,  hemangiomas, 
lipomatosis.  10%  of  those  with  Cowden 
syndrome  may  develop  follicular  cell-
derived  thyroid  carcinoma  [5].  Thyroid  in 
Cowden’s  syndrome  may  have  multiple 
adenomatous  nodules,  follicular  nodules, 
lymphocytic thyroiditis. The thyroid cancer 
may be papillary (60%) or follicular (40%). 
After Harb [23] up to 10% of patients with 
Cowden’s  syndrome  may  have  follicular 
carcinoma. Loss of function PTEN mutation 
may be identified by immunohistochemistry 
with a sensitivity of 100% and a specificity 
of  92.3%  [27].  Thyroid  carcinoma  has  the 
highest  familial  incidence  in  CS.  Out  of 
2723  patients  with  CS  664  had  thyroid 
cancer. PTEN mutation is associated with a 
nine  fold  increase  of  risk  for  pediatric 
thyroid  cancer.  Close  surveillance  of 
children  carrying  PTEN/PHTS  mutation 
must begin as soon as mutation is detected 
[28], at the age of 18 years or 5 years before 
the  age  of  the  earliest  detect  case  in  the 
family  [26].  Individuals  with  PTEN  germ-
line  mutation  must  be  monitored  followed 
for  cancer  following  specific  recom-
mendations [29].  
3. Carney’s complex is  an autosomal 
dominantly  inherited  syndrome  due  to 
PCKR1-x  (proteinkinase  A  regulatory 
subunit  type  1α)  situated  on  chromosome 
2p16 [5,30]. 500 cases have been registered 
in  the  NIH-Mayo  Clinic  and  Cochrane 
database.  Non  thyroidal  illnesses  in  the 
syndrome may be [5,30]: primary pigmented 
adrenocortical  disease  (60-75%),  cardiac 
mixoma,  skin  mixoma,  lentiginosis,  blue 
nevi,  pituitary  adenomas  (acromegaly), 
testicular  tumors,  ovarian  cysts.  The 
incidence of thyroid cancer in the syndrome 
varies between 4 and 60% [5] or 10-25 % 
[30] and the carcinoma may be of papillary Familial nonmedullary thyroid cancer    225 
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or  follicular  type  [5].  Papillary  thyroid 
cancers  have  an  aggressive  behavior  in 
Carney’s complex [30]. 
4.  Werner’s  syndrome  (WS)  is 
produced by mutation of WRN gene situated 
on  chromosome  8p11-p12.  The  main 
features  of  WS  are  [5,31]:  abnormal  body 
habitus  (short  stature,  stocky  trunk  and 
spindly limbs), premature aging (grey hair, 
catharacts,  osteoporosis)  sleroderma-like 
changes of the skin,  muscular  atrophy  and 
endocrine  diseases:  diabetes  mellitus, 
hypogonadism  [5,31].  The  incidence  of 
thyroid cancer in WS is up to 18% (3% in 
non  Japanese  and  14%  in  Japanese 
population) and the histology may be: PTC: 
84%, follicular: 14 %, anaplastic 20% [5]. 
5.  Pendred’s  syndrome  (PS)  is  an 
autosomal  recessive  disease  caused  by 
mutation of LSC26A4 gene which encodes 
pendrin  a  gene  involved  in  iodide 
organification in the thyroid and in the the 
maintenance of normal anion transport and 
endocochlear  potential  in  the  inner  ear 
[32,33].  PS  is  characterized  by  bilateral 
sensoneuronal  deafness,  goiter  and 
hypothyroidism.  Follicular  thyroid 
carcinoma and Hurthle cell carcinoma were 
described  in  6  Thai  families  with  PS  by 
Snabboon T [34] and in an isolated case of 
PS by Bashir [35].  
 
 
CONCLUSIONS 
Follicular  cell-derived  thyroid  cancer 
has the highest increase in prevalence during 
last  years  due  to  routine  ultrasound 
examination of the thyroid gland. 5-10 % of 
nonmedullary  thyroid  carcinomas  may  be 
familial  forms,  defined  as  three  or  more 
affected individuals in a family. Relatives of 
patients  with  FNMTCs  have  a  3-9  fold 
increased  risk  of  developing  the  same 
disease, which seems to be the highest risk 
among all cancers. 
Familial thyroid cancer occurs as non-
syndromic  (pure)  form  in  which  thyroid 
cancer  is  the  predominant  feature  or  as 
syndromic  forms  in  which  other 
malignancies  are  predominant  and  thyroid 
cancer is associated with a known frequency. 
Although  at  least  four  suscepytibility 
loci are probably involved in the occurrence 
of  pure,  non-syndromic  thyroid  cancer 
(TCO,  FPTC/PRN,  NMTC1,  MNG1)  the 
candidate gene have not been described until 
now. The inheritance seems to be autosomal 
dominant  with  reduced  penetrance  or  age-
related penetrance. 
The  main  features  of  pure  familial 
thyroid  cancers  are:  the  association  with 
other  thyroid  disease:  nodular  and 
autoimmune  diseases,  bilaterality, 
multicentricity,  more  aggressive  behavior 
with  trend  to  spread  out  of  the  thyroid, 
greater  rate  of  persistence  and  recurrence 
within  thyroid  bed,  frequent  distant 
metastases and lower survival rate. 
Knowing  the  aggressiveness  of 
FNMTCs,  affected  individuals  must  be 
prospectively  researched  by  screening, 
aggressively treated and closely monitored. 
Their  relatives  must  be  also  monitored  for 
early  diagnosis  known  the  phenomenon  of 
genetic anticipation. 
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